Molecular phenotyping has expanded from small sample sizes to larger complex studies and are now a common element in genetic studies. When large scale studies add a molecular phenotyping component, balancing omics batches for the factors of interest (e.g. treatment), regardless of the initial sample collection strategy always improves power. Where possible, confounding sources of experimental error that are not of interest (sample collection blocks and data collection plates) improves power as does planning batches for molecular phenotyping based on constraints during initial sample collection. Power for testing differences in molecular phenotypes is always higher when accounting for the entire experimental design during modeling. The inclusion of metadata that tracks sources variation is critical to our shared goals of enabling reproducible research.
Introduction
Experiments using omics technology have transitioned from simple small scale studies to large scale populations. Omics technologies are now deployed in experiments that can encompass genotypes at many loci and/or a diverse array of environmental exposures. Such in depth studies increase our understanding of molecular phenotypes, allowing us to connect molecular signatures to complex traits. In several species, genetic reference panels (GRPs) have been developed and densely genotyped; in human populations large scale studies are now being assayed for omics phenotypes. The attraction to GRPs is the ability to survey the same set of genotypes under different conditions for different phenotypes. GRPs have been used to uncover the genetic basis of flowering time in Maize (1), telomere length (2), male infertility (3), fitness in C. elegans (4) , and relationships between nutrition and lifespan in Drosophila (5) . Molecular phenotypes for GRPs have become an important component to understanding complex traits (6) , (7), (8) and responses of biological systems to environmental inputs (9, 10) . Human genetics has fully embraced both the challenge and the promise of multi-omics experiments with many large scale studies of diseases adding a molecular phenotyping arm.
The application of omics technologies to large experiments brings new challenges to experimental design. For large scale human studies, the wealth of clinical information collected makes repurposing and adding omics data a much more attractive option than a completely new study. For GRPs the ability to compare omics data among treatments/conditions opens and exciting window into complex systems. The goal of experimental design is to maximize the power for detecting and accuracy of estimating effects of interest given practical constraints. In the sample collection phase of large human genetic studies, experimental design considerations are discussed and effects included in subsequent phenotypic models. In crop plants, the fields needed to grow GRPs are large, going beyond what could reasonably be considered a homogeneous environment and a credible randomized complete block design. Yet, there is persistent failure to acknowledge this in the design and analysis of molecular phenotypes. The number of distinct genotypes makes it impossible to collect all study material on the same day, or in a particular circadian window, by a single person, meaning that there will be sources of variation that contribute to the measurement of the molecular phenotype. These are usually factors for which studies of traditional phenotypes would demand a formal experimental design (11) . Further complicating the experiments are the data acquisition phases that harbor their own logistical considerations. Thus far how sample collection constraints, should be balanced with design considerations for data acquisition using omics platforms in the subsequent phase of the study has often been neglected in the reporting of molecular phenotypes. Some studies report on their consideration of data acquisition when collecting omics data (16, 17) , but most do not provide this level of detail in the reported methods.
Given a specific experimental design for sample collection, is there an optimal way to distribute samples over sequencing lanes, batches, and machines? Experimental design is as critical for acquisition of molecular phenotypes as for sample collection. For example, in RNA-seq, if lanes are confounded with treatments, as suggested by Illumina as a way to minimize the impact of the index hopping (12) , inferences about treatment effects will be compromised (13) . In metabolomics experiments, effects of batch, machine, and column need to be considered (14) . Metabolomics batches are typically small (less than 50) relative to batches for gene expression data (96/384). Effects of initial sample concentration are important to consider for prior to data acquisition to ensure that ionization conditions are comparable across batches (15) . Here we use simulations to show, first, how analysis that fails to take into account sources of variation for sample collection and data acquisition results in dramatic reduction of power for inferences, and second; how thoughtful design can be used to optimize power for tests of molecular phenotypes.
Omics experiment have four main stages, sample development, sample collection, sample preparation, and data acquisition (Fig. 1) . In many experiments, there will be more steps that can introduce variation. Without loss of generality, we consider two general sources of variation (sample development/collection and sample preparation/data acquisition) in order to demonstrate the cascade effects of experimental design choices. The technological or practical capacity for processing data is likely different during sample collection and data acquisition. There are two general randomization approaches for dealing with the transition from sample collection to data acquisition. Batches can be randomized reflecting the original sample collections scheme (conditional randomization -CR) or re-randomized (RR). We evaluate the effect of conditional randomization and re-randomization on the power of tests for genotype and treatment effects. Our findings suggest that power for detection of effects depends upon due consideration of sample collection limitations when planning the data acquisition phase.
Results
Molecular studies often have broad hypothesis (for example: there is a difference in gene expression between the control and treatment for at least one gene; or changes in at least one of the measured metabolites reflects the underlying metabolic cause of disease and will be independently predictive of condition in other samples) and reuse of the data for other hypotheses is common. As different hypotheses will suggest different designs to optimize power, it is helpful to define primary and secondary goals for the study before choosing a design. However, when such studies are added later to an existing study, this is not always possible. Here we consider the impact of the sampling design on two common null hypotheses for molecular phenotypes: the absence of genotypic differences and the absence of differences in treatment effect between genotypes. Practical advice for omics data acquisition is provided for situations where there is no ability to integrate the design for sample collection and omics data acquisition.
Tracking the experimental design is crucial: Although advanced methods exist to account for hidden sources of variation (e.g., 17), the most common approach to statistical testing in molecular phenotypes is to ignore the experimental design in the sample collection phase and sometimes also during the data acquisition. While normalization for data acquisition batch effects is common, when batch and treatment effects have complicated relationships normalization strategies are likely to fail (17) and can lead to radically misleading results (18) . We compared models that ignore block effects (during sample collection) and batch effects (during omics data acquisition) to models that account for these effects. The models that do not track the design in either or both stages of the experiment have less power for detecting genotype effects than those that do track the design (Fig. 2) . Models that ignore block or batch effects, even when they are smaller than the biological variation, have less power to detect effects of interest than when variance between blocks and batches is relatively large and accounted for in the model. Other trends, such as decreasing power when batch variance increases are intuitive, yet striking in the magnitude of the impact.
Conditional randomization is better than re-randomization in tests for genotype effects: How to best match samples between sample collection blocks and data acquisition batches? One option is to keep the experimental units (e.g. genotypes) collected in the same sample collection block together in the same batch for data acquisition (conditional randomization, CR). Alternatively, the samples can be randomized to new batches for data acquisition without regard to the original sample collection block (re-randomization, RR) (Fig. 3A) . For illustration consider the simplest case where all samples for a single replicate can be collected as a single block and then data acquired in batches of equal size to the blocks. Here, CR improves power for detecting genotypic differences (Fig. 3B) . When the experimental errors of blocks and batches are completely confounded they are jointly estimated as a single effect leaving more degrees of freedom for the estimation of the residual error (See supplementary material for a theoretical argument). Effectively, all genotypes are measured simultaneously in the same 'environment', thereby reducing the variance in the between genotype comparison. In contrast, complete re-randomization (RR) results in the need to separately estimate block and batch effects. Effectively constructing different environments for each genotype and making the accurate estimation of these effects necessary for comparing genotypes. In a GRP, the small number of replicates relative to the number of genotypes limits the estimation of design effects such as block and batch even in this relatively simple cases where the block and batch variation are independent from each other and from the effect of genotype (See Supplement). In more realistic scenarios where sampling is conducted in partial blocks within replicates ( Fig. 3C) , CR can have much higher power for the detection of genotype effects than RR. (Fig. 3D) . In comparisons of genotypic effects CR is markedly more powerful than RR when comparing genotypes in the same partial block/batch combination. When comparing genotypes across partial blocks/batches power is comparable in CR and RR (Fig. 3D) . There is then nothing to be lost, and some power to be gained by using CR designs for data acquisition of molecular phenotypes in the comparison among genotypes.
The relative size of the block and batch matters: For some experimental systems (e.g. maize) the sample collection phase can have relatively large blocks, while in other systems (e.g. mouse) the sample collection phase is typically constrained to much smaller blocks. In human genetics sample collection is a process that is reflective of the unique constraints of these studies. The relative size of the sample collection block compared to the data acquisition batch varies among studies. While gene expression assays can be processed in relatively large batches (RNA-seq in multiplexed batches of 96/384), smaller batch sizes are more common for other omics platforms (12-48 in metabolomics). The impacts of batches can be easily demonstrated (13, 15) (Supplementary Fig. S3 and S4) The size of the batch correspondingly affects the number of batches needed, with smaller batch sizes requiring a larger number of batches to complete an experiment. We evaluated power to detect a QTL effect given different block and batch size/number. We compared RR and CR for different amounts of variance (Fig. 4, Supplementary Fig. S2 ). Power is similar when the number of blocks is small relative to the number of batches (Fig. 4a) . For medium and high variance in blocks and batches CR has higher power. Power is higher when the size of the block is equal to or greater than the size of the batch. (Fig. 4a) In CR, the highest power is always when block and batch size match (Fig. 4b) . In contrast, for RR larger blocks are more important than larger batches (Fig. 4b) . When block variance is low block size does not matter (Fig. 4B) . When block and batch variance are equal and the variance is low or high CR and RR are very similar in their power to detect QTL effect (Fig 4c) . As the block and batch size increases, CR improves in power faster than RR (Fig 4c) .
Power for testing treatment effects depends on pairing treatments. The effect of treatment, such as tissue differences in mice, drought or other environmental stress effects in plants, and sex differences in Drosophila may be sampled in the same block for a particular genotype (incomplete block design, IBD; Supplementary Fig. S1A ) or may require separation for sampling (e.g. planting density (19) ) (split-plot design, SPD; Supplementary Fig. S1B ). The SPD has lower power for the whole plot (treatment) effect relative to the IBD for phenotypes sampled during the sample collecting phase (11) . Most human genetic studies collected over multiple sites will be some variant of the SPD as sites are often different for confounding factors such as age and race. We simulated 192 genotypes in a natural population with varying treatment effects and without interactions between the treatment and genotype (Supplementary Table 3) in both an IBD and SPD. Data acquisition was simulated in three ways: 1. in batches that retain the block randomization (CR); 2. pairing samples from the same genotype and block but from different treatment levels (for instance treatment-control) and then randomizing these pairs into batches (P-RR) and pairing samples from the same genotype and block but from different treatment levels (for instance treatmentcontrol) and then keeping half of the genotype treatment pairs together in a batch (P-CR) ( Supplementary  Fig. S1A,B) . Power is lower for SPD than IBD for the test of treatment, since the treatments are confounded with block (Fig. 5) . However, as long as the treatments for a genotype are paired in the data acquisition stage (P-RR and P-CR), power in the SPD is similar (Fig 5) . The implication for human genetic studies is that molecular phenotypes should be acquired in batches balanced for tests of the effects of interest, regardless of the initial sample collection.
Discussion
One of the barriers to successful omics data analysis and subsequent integration is the treatment of experimental effects as a post-hoc normalization problem. By focusing on post-hoc removal of technological effects, strong assumptions are needed. Post-hoc normalization strategies are not guaranteed to succeed (18) , and they cannot fix issues with confounded effects in the design (11, 13) . Tracking the experimental design and including those effects in the model when testing for the effects of interest improves power dramatically. In large studies of phenotypes such as plant yield or bone density, it is common to account for sources of variation in the design and in particular at the time of measurement. While tissue collection and downstream data acquisition for molecular phenotypes may be more complex than organismal phenotypes, the increased cost and complexity of phenotyping does not change the necessity for careful experimental design. Studies likely consider these elements during planning, but fail to report these details. More exposition of sample collection protocols in and the design of the data collection strategies are critical to improving reproducibility. Further, fitting models that explicitly account for the complete design provide substantial gains in power compared to ignoring these effects. Randomization protocols for omics data that only consider the logistical constraints for omics data acquisition are not necessarily optimal designs. Optimal strategies for linking design between sample collection and data acquisition depend on logistical constraints (e.g. the relative size of blocks and batches) but in all cases power gains can be achieved by accounting for the experimental design for the entire scope of the experiment.
Optimal designs will depend upon the specific hypotheses to be tested. For a hypothesis about a treatment effect, if the sample collection forced treatments to be in separate environments (a "split plot") then a randomization for sample collection that pairs the same genotype with all treatments for data acquisition will have more power than keeping the treatments separated in batches. In human genetic studies of molecular phenotypes, it is common to account for covariates (e.g. age, sex) as well as technical factors such as batch in the statistical model (17, 21) . Human genetic studies are often "split plot" designs with some confounding of sample collection with factors of interest/importance like sex and age, treatment arm, etc. In these cases, we recommend a restricted re-randomization that balances potentially important covariates over batches, rather than an unrestricted re-randomization (Fig 5, Supplementary Fig. 1 ).
When studies are repurposed for omics experiments, it is of critical importance to both keep track of sources of variation in the original study, and to balance omics blocks for the treatments of interest for the omics experiment. Similar to (13) our simulations show that for comparisons between conditions pairing samples by condition/treatment during omics data acquisition minimizes the confounding between technical sources of variation during omics data collection and the hypothesis of interest. Treatments should not be confounded with sources of variation during data acquisition, e.g. lanes, despite issues that may arise (e.g index hopping). Instead in Illumina studies larger multiplexes, and more technical replicates are preferred. The use of unique i5/i7 barcode combinations also facilitates the detection of this phenomenon. For metabolomics, balancing the small batches so that important contrasts among samples are captured within the batch is critically important (e.g. (15)).
The challenge to large scale molecular phenotyping studies, particularly those investigating multi-omics, is in the number and scope of hypotheses. Secondary data analyses are an important part of the justification for conducting these experiments. Logistical constraints create situations where it is unlikely that the optimal design for all possible hypotheses can be developed -there will be trade-offs. While difficult, investigators should actively manage these trade-offs during design of the experiments. It is of critical importance that the experimental design process is realistic about the sources of variation in the entire experimental process. Ignoring sources of variation can result in dramatic loss of power. For investigators partnering with companies for data acquisition services, information about batches, and randomization within and between batches is of critical importance. Companies that do not disclose this information may confound sources variation obscuring true differences and potentially leading to false positives due to technological effects. Lack of information about batches will lead to increased challenges in reproducing results.
The power of large molecular studies can be improved by jointly planning the experimental design of data acquisition and sample collection to optimize block and batch sizes. We show that higher power is obtained, with the same data, if the statistical model of molecular omics phenotypes explicitly includes the experimental design of both the sample collection and the data acquisition phases -and that further power gains are possible if the design for data acquisition is reflective of constraints of the sample collection phase. If batch variance is expected to be high, smaller batches with samples handled jointly throughout the process will maximize power. Researchers should avoid the temptation to continually re-randomize samples during omics data processing. Instead, a randomization that balance for effects of interest that is maintained will both result in fewer handling errors by technical staff, and higher power for hypothesis tests.
Even when the technical variance is small relative to the biological variation, substantial power can be gained by accounting for technical sources of variation. The immediate implication is that failure to share meta-data related to sample collection and data acquisition, will result in increased difficulty in reproducing results. The important endeavor of increasing the transparency, reliability and reproducibility of results demands that detailed information about how data are collected, in all the stages of the experiment, are critical to future studies. , 2 ) where the additive genetic effect was simulated with a QTL effect (α i ) using R/qtl (20) . Independent of the QTL we simulated random variation from sample collection  ki ~ N(0, 2 ), data acquisition , P j = (P 1 ,...P 4 ) ~ N(0, 2 ), and random variation due to noise ,
where random noise was scaled relative to 2 . By varying α, 2 , 2 and 2 a total of 180 conditions were simulated with 1000 iterations each (Supplementary Table 1 ). The different randomization elements of the design were evaluated by arranging the block/batch variance according to the design being evaluated.
Population simulation
Block design: Datasets were simulated for 192 genotypes with 2 treatments and 4 replicates. For each replicate, b blocks were simulated from multivariate normal distribution (MVN) assuming independent block effects. For each replicate, genotype/treatment pairs were assigned to each block randomly (note that genotypes within blocks vary rep to rep -genotype set in rep1, block1 are not the same genotype set in rep 2, 3 or 4, block 1). For each simulated dataset, the phenotype was simulated as the sum of genotype effect, treatment effect, rep effect, block effect and random error for i = 1 to 192 genotypes, j = 1 to 2 treatments (control vs treatment), k = 1 to 4 replicates and l = 1 to b blocks.
Split Plot Design:
Using the same parameters as described above for the genotypic effects. For each replicate, b blocks were simulated from multivariate normal distribution (MVN) assuming independent block effects. For each replicate, 4 of the blocks were randomly assigned to treatment 1 and the other four of them assigned to treatment 2 and 192 genotypes were assigned randomly (note that genotypes within blocks vary rep to rep -genotype set (48 genotypes) in rep1, block1 are not the same genotype set in rep2, 3 or 4, block 1). For each simulated dataset, the phenotype was simulated as the sum of genotype effect, treatment effect, rep effect, block effect and random error for i = 1 to 192 genotypes, j = 1 to 2 treatments (control vs treatment), k = 1 to 4 replicates and l = 1 to n blocks. (12) and run time drift (14) .
Without loss of generality, we can consider Stages 1 and 2 together as sample collection, and Stages 3 and 4 together as data acquisition. When the block size is bigger than the batch size and (B) when block size is less than batch size. Failing to incorporate block and/or batch effects has a large effect on power. Accounting for batch effects has higher power than failing to account for batch effects and the additional impact of accounting for block are large with power gains dependent on the size of the block with high block variance increasing the importance of accounting for the block effect. Table 3 ). On the y-axis is power calculated as in B and on the x-axis is the variance due to batch, with a block variance of 1 and error variance of 0.4. As the variance between batches increases the power for the test of the genotype effect decreases in RR. Power between genotypes in different batches in CR is virtually identical to the RR design, while power between genotypes in the same batch in the CR design is much higher. For the P-RR design the average power for genotype effects is shown without regard to the batch. 
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Simulation 1. Conditional Randomization vs Re-Randomization across replicates
For the first simulation, our goal was to understand the effect of variation due to sample collection (block) and variation due to data acquisition (batch). In this simple situation a single replicate fits into a single block for sample collection and a single batch for data acquisition. Data were simulated for 96 inbred lines (RILs) with one major QTL in 4 independent replicates (4 blocks each containing 96 genotypes). After sampling, experimental units were either kept together on a plate for data acquisition (CR) or randomized without regard to the initial sample collection phase (RR).
We simulated each source of variation independently. Here block effect is the effect of replicate.
For r = 1 to r replicates, the effect of each replicate is drawn independently from ~ (0, 2 ). For p = 1 to p batches, the effect of each batch is drawn from ~ (0, 2 ). For g genotypes we simulated a single QTL with an additive effect using R/qtl (Broman et al. 2003 ) and drew from ~ ( − ′ , 1), where − ′ was the QTL effect. Each individual also had two sources of random error associated with each observation, one at sample collection 1 = ( 1 , . . )~ (0, 1 2 ) and one at data acquisition 2 = ( 1 , . . )~ (0, 0.2 * 1 2 ). The trait value for an individual i in rep r and batch p is calculated as:
In general, let be the set of individuals having genotype g, and | | be the number of individuals in , similarly and will denote the set of replicates and batches for individuals having genotype g. The expected mean trait value for genotype g is (without loss of generality, the expectation is conditional on the random effects rep and batch): 
